Rhythm Pharmaceuticals, Inc., a leader in the biopharmaceutical industry, is pioneering innovative therapeutics for rare genetic diseases of obesity. Focused on the development and commercialization of its products, the company's premier offering is IMCIVREE, a groundbreaking melanocortin-4 receptor for the treatment of a host of rare obesities - including pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. Furthermore, Rhythm Pharmaceuticals is actively creating setmelanotide, which currently undergoes Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. Founded in 2008, Rhythm Pharmaceuticals was formerly known as Rhythm Metabolic, Inc. before undergoing a name change in October 2015. The company is headquartered in Boston, Massachusetts - a testament to its dedication to developing advanced medical treatments of the highest caliber.
Rhythm Pharmaceuticals's ticker is RYTM
The company's shares trade on the NASDAQ stock exchange
They are based in Boston, Massachusetts
There are 51-200 employees working at Rhythm Pharmaceuticals
It is rhythmtx.com
Rhythm Pharmaceuticals is in the Healthcare sector
Rhythm Pharmaceuticals is in the Biotechnology industry
The following five companies are Rhythm Pharmaceuticals's industry peers: